Albright F, Burnett CH, Smith CH, Parson WW. Psudohypoparathyroidism: an example of Seabright Bantam syndrome. Endocrinology, 1942; 30: 922-932.

Michael A Levine. An update on the clinical and molecular characteristics of psudohypoparathyroidism. Curr Opin Endocrinol Diabetes Obes, 2012; 19(6): 443-451.

Merlin G Butler. Genomic imprinting disorders in humans: a mini review. J Assist Reprod Genet, 2009; 26: 477-486.

KAPLAN, N.M. 2002. Pheochromocytoma (with a preface about incidental adrenal masses). In Kaplan’s Clinical Hypertension. N.M. Kaplan, Ed.: 434–454. Lipincott Williams & Wilkins. Philadelpia.

STREETEN,D.H.P.&G.H.ANDERSON, JR. 1996. Mechanisms of orthostatic hypotension and tachycardia in patients with pheochromocytoma. Am. J. Hypertens. 9: 760–769.

ITO, Y., Y. FUJIMOTO & T. OBARA 1992. The role of epinephrine, norepinephrine, and dopamine in blood pressure disturbances in patients with pheochromocytoma. World J. Surg. 16: 759–764.

Grumbach MM, Shaw EB. Further studies on the treatment of congenital adrenal hyperplasia with cortisone: IV, eefect of cortisone and compoubd B in infants with disturbed electrolyte metabolism. Pediatrics 1998; 102: 215-21.

Pang S, Clark A. Congenital adrenal hyperplasia due to 21-hydroxilase deficiency: newborn screening and its relationship to diagnosis and treatment of the disorder. Screening 1993; 2:105-39.

Therrell BL. Newborn screening for congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001; 30: 15-30.